Wellington Management Group LLP Buys 11,763 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Wellington Management Group LLP increased its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 8.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 147,499 shares of the biotechnology company’s stock after purchasing an additional 11,763 shares during the quarter. Wellington Management Group LLP’s holdings in Astria Therapeutics were worth $1,624,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ATXS. Quest Partners LLC boosted its stake in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after buying an additional 3,112 shares during the period. PDT Partners LLC bought a new stake in shares of Astria Therapeutics in the 3rd quarter worth about $140,000. SG Americas Securities LLC purchased a new position in shares of Astria Therapeutics during the 3rd quarter worth about $155,000. Hsbc Holdings PLC bought a new position in Astria Therapeutics during the 2nd quarter valued at about $171,000. Finally, Intech Investment Management LLC purchased a new stake in Astria Therapeutics in the 3rd quarter worth about $228,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Wall Street Analyst Weigh In

ATXS has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research note on Tuesday, December 10th. Oppenheimer boosted their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Price Performance

Shares of ATXS stock opened at $9.36 on Thursday. The company has a market capitalization of $528.22 million, a P/E ratio of -4.48 and a beta of 0.67. The company’s 50-day simple moving average is $10.72 and its two-hundred day simple moving average is $10.70. Astria Therapeutics, Inc. has a one year low of $5.88 and a one year high of $16.90.

Astria Therapeutics Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.